The link between estrogen fluctuations and increased depression in postmenopausal women underscores the need for targeted therapeutic approaches. As the demand for effective menopausal treatments grows, companies must adapt their strategies to develop personalized MHT solutions that address these psychiatric symptoms. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 16 ranked evidence items (6 high-relevance).